John Onopchenko, CEO of Endologix, said, “I am very excited to have someone with Jeff’s credentials and industry knowledge joining our executive team. His proven track record of transformational leadership, operational excellence, and delivering results will be invaluable to Endologix. We remain focused on building a cohesive team and a strong culture of accountability, while continuing to innovate and position the Company for further operational improvements.”
Brown brings to Endologix 24 years of experience as a general manager, chief operating officer, supply chain executive, sales leader, consultant, and lecturer. Most recently, he was general manager of a multi-site joint venture between Johnson & Johnson and Steris Corporation, where he led significant improvements across operations, quality, engineering, and supply chain. Prior to that, he was chief operating officer for Chatham Industries, where he helped successfully orchestrate a leveraged buyout and turnaround of the firm. Prior to that, Brown worked for five years as general manager at Boston Scientific Corporation, where he led a critical site transformation and sat on the global supply chain management board. Brown also worked for seven years as worldwide operations manager at Johnson & Johnson and for five years leading sterilization operations across the United States, European Union, and Far East for Haemonetics Corporation.
Brown commented, ”I am thrilled to be taking on this critical leadership role at Endologix, particularly during this transformational time. I look forward to working with the team to improve operations and to leverage our talent and innovative technology, with the ultimate goal of delivering superior products and services to our patients.”
Brown earned his MBA from Babson College in Wellesley, Mass., and his bachelor of science degree in microbiology from the University of New Hampshire, Durham.
Endologix Inc. develops and manufactures minimally invasive treatments for aortic disorders. The company's focus is endovascular stent grafts for the treatment of abdominal aortic aneurysms (AAA). AAA is a weakening of the wall of the aorta, the largest artery in the body, resulting in a balloon-like enlargement. Once AAA develops, it continues to enlarge and, if left untreated, becomes increasingly susceptible to rupture. The overall patient mortality rate for ruptured AAA is approximately 80 percent, making it a leading cause of death in the United States.